Introduction
Neural survival and differentiation are influenced by the cellular redox condition (Kane et al., 1993) . Thioredoxin (TRX) is a small 12 kDa multifunctional protein having a redox-active disulfide/ dithiol within its active site sequence, -Cys-Gly-Pro-Cys-, and operates together with NADPH and thioredoxin reductase as a protein disulfide-reducing system (Holmgren, 1985) . Several reports have shown that TRX-dependent redox regulation is closely involved in the signal transduction mediated by activator protein-1 (AP-1), nuclear factor-B, p53, apoptosis-signaling kinase 1 (ASK1), and p38 mitogen-activated protein kinase (MAPK; Hirota et al., 1997; Saitoh et al., 1998; Hashimoto et al., 1999; Ueno et al., 1999) . TRX is widely distributed and induced by various stresses (Nakamura et al., 1997; Masutani et al., 1999) . TRX expression is also elevated by hemin, an inducer of differentiation in K562 erythroleukemia cells (Kim et al., 2001) , or cAMP analogues in retinal pigment epithelial cells (Yamamoto et al., 1997) . In the regulatory region of the TRX gene, there are several promoter-specific transcription factor 1 binding motifs, an antioxidant-responsive element, and a putative cAMPresponsive element (CRE). In neuronal tissues, TRX is induced in astroglia after ischemia (Tomimoto et al., 1993) and in motor neurons after nerve injury (Mansur et al., 1998) . TRX is known to have a cytoprotective effect against oxidative stress (Nakamura et al., 1994) and neuroprotective activity (Hori et al., 1994) . Furthermore, overexpression of TRX in transgenic mice attenuates focal ischemic brain damage . TRX was also reported as a neurotrophic factor for central cholinergic neurons and has neurotrophic activity (Endoh et al., 1993) , although the molecular basis of this effect has not been elucidated.
Nerve growth factor (NGF) and the other members of the neurotrophin family, such as brain-derived neurotrophic factor, have profound effects on neurons, including the promotion of survival and differentiation (Lo, 1992) . NGF has been reported as a potential therapeutic agent in neurodegenerative disorders linked to aging, such as Alzheimer's disease (Connor and Dragunow, 1998) . The current understanding of these mechanisms depends mostly on studies of NGF action on the pheochromocytoma cell line PC12 (Greene and Tischler, 1976) . On exposure to NGF, PC12 cells differentiate into sympathetic neuron-like cells. The signal is initiated by the binding of NGF to its high-affinity receptor TrkA on the plasma membrane (Kaplan et al., 1991) and transduced by activation of ras and the MAPK cascade (Thomas et al., 1992) . NGF treatment in PC12 cells leads to the activation of immediate-early genes (IEGs), such as c-fos, which are believed to be critical to NGF action (Milbrandt, 1986) . NGF activates the c-fos gene through several elements, including the serum re-sponse element (SRE; Treisman, 1986) and CRE (Ginty et al., 1994; Ahn et al., 1998) .
The aim of the present study is to investigate the possible roles of TRX as a neurotrophic cofactor in NGF-dependent outgrowth of PC12 cells and the NGF-mediated signal transduction pathway. We report here that TRX plays an important role in the NGF-mediated signal transduction and neurite outgrowth in PC12 cells.
Materials and Methods
Cell lines and culture. NGF, polyethylenimine (PEI), and 2Ј-amino-3Ј-methoxyflavone (PD98059) were purchased from Sigma (St. Louis, MO). Hoechst 33324 was purchased from Molecular Probes (Eugene, OR). Cells of the rat pheochromocytoma tumor cell line PC12 were maintained in RPMI 1640 medium (Invitrogen, Grand Island, NY) with 10% heat-inactivated horse serum and 5% heat-inactivated fetal calf serum (FCS) supplemented with antibiotics (100 IU/ml penicillin and 100 g/ml streptomycin) at 37°C in a humid atmosphere containing 5% CO 2 .
Plasmids. The pTrx-chloramphenicol acetyltransferase (CAT) plasmids were constructed as described previously (Taniguchi et al., 1996) . The HindIII-BamHI inserts from the pTrxCAT vectors were subcloned into pBluescript II KS (ϩ) (pTRXblue vectors). The pTRX (Ϫ1148)-luciferase (Luc), pTRX (Ϫ1062)-Luc, pTRX (Ϫ352)-Luc, and pTRX (Ϫ263)-Luc vectors were constructed by ligating the KpnI-BamHI fragments of the pTRXblue vectors into the KpnI-BglII sites of the pGL3 basic vector (Promega, Madison, WI). The ApaI-PvuII insert of the pTRX (Ϫ263)-Luc vector was excised, filled in, and self-ligated to produce the pTRX (Ϫ217)-Luc vector. The pGL3-c-fos (Ϫ40, ϩ42) and pGL3-c-fos (Ϫ99, ϩ42) luc vectors were constructed by subcloning an MluI-HindIII fragment of the Fos-40 luc (Masutani et al., 1997) and the pFDE-luc vectors into the MluI-HindIII site of the pGL3 basic vector (Promega). SRE3-luc was constructed as described previously (Masutani et al., 1997) . pFDE-luc was constructed by subcloning a BamHI-HindIII fragment of FDE-CAT (Trouche et al., 1993) into the BglII-HindIII site of the pGL2 basic vector (Promega). PTrxCREwt-Luc and pTrxCREmtLuc vectors were constructed by inserting CRE wild-type (wt) or CRE mutant (mt) oligonucleotides into the XhoI-PuvII site of the pTRX (Ϫ1148)-Luc, respectively. The pCDSR␣-TRX, pCDSR␣-TRX (C32S/ C35S), and pcDNA3TRX (32S/ 35S) vectors were constructed as described previously . The BamHI inserts from pCDSR␣-TRX and pCDSR␣-TRXm (Tagaya et al., 1989; Hirota et al., 1997) were subcloned into the BamHI site of pBluescript II KS [pBS-wtTRX, pBS-antisense, and pBS-double mutant (dm) TRX]. pBI-enhanced green fluorescent protein (EGFP)-wtTRX, pBI-EGFP-antisenseTRX, and pBI-EGFP-dmTRX (32S/35S) were constructed by ligating the EcoRV-XbaI fragments of the pBSwtTRX, pBS-antisense, and pBS-dmTRX vectors into the PvuII-NheI sites of the pBI-EGFP vector (Clontech, Palo Alto, CA), respectively. All the constructs were controlled by direct nucleotide sequencing using a Thermo Sequenase II dye terminator cycle sequencing kit (Amersham Biosciences, Arlington Heights, IL). The pRL-TK vector was purchased from Promega. pcDNA3 was purchased from Invitrogen. The oligonucleotides used for construction of vectors and the electrophoretic mobility shift assay (EMSA) were as follows: CREwt, forward, 5Ј-CGCCTCCCACCGTCACGGGCAGTGC-3Ј; and reverse, 5Ј-TCGAG-CACTGCGCGTGACGGTGGGAGGCGGTAC-3Ј; and CREmt, forward, 5Ј-CGCCTCCCACTATCACGGGCAGTGC-3Ј; and reverse, 5Ј-TCGAG-CACTGCGCGTGATAGTGGGAGGCGGTAC-3Ј.
Western blot analysis. Cells were collected and washed twice with icecold PBS, and then lysed with a solubilizing solution (10 mM Tris-HCI, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 0.1 mM PMSF, 8 g/ml aprotinin, and 2 g/ml leupeptin) on ice for 30 min. The extracts were cleared by centrifugation. Cell lysates were kept at 95°C for 5 min and then separated by 15% SDS-PAGE. The separated proteins were transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA). The membrane was treated with 10% (w/v) skim milk in PBS containing 0.05% Tween 20 overnight, and incubated with anti-mouse TRX rabbit polyclonal antibody (dilution, 1:1000; Redox Bioscience, Inc.; Takagi et al., 1998c ) for 1 hr, followed by peroxidase-conjugated anti-rabbit IgG (dilution, 1:5000; Amersham Biosciences) for 1 hr. The epitope was visualized with an ECL Western blot detection kit (Amersham Biosciences). We reported previously that this anti-mouse antibody cross-reacts with rat TRX (Takagi et al., 1998a,b) .
Northern blot analysis. Total RNA was extracted using TRIzol reagent according to the manufacturer's instructions (Maruyama et al., 1997) . Twenty micrograms of total RNA were electrophoresed and transferred to maximum-strength Nytran nylon (Schleicher & Schuell, Keene, NH) with a Turbo-Blotter system (Schleicher & Schuell). The filter was hybridized with a mouse TRX probe, which cross-reacts with rat TRX mRNA as reported previously (Takagi et al., 1998a,b) .
Electrophoretic mobility shift assay. EMSA was performed as described previously (Kim et al., 2001) . Nuclear extracts were prepared from exponentially growing PC12 cells incubated with NGF (50 ng/ml) at various time points. Aliquots of 10 g of unclear extracts were incubated with 32 P-end-labeled double-stranded oligonucleotides in a binding reaction buffer containing 20 mM HEPES, pH 7.9, 0.02 mM EDTA, 14% glycerol, 1 g of poly(dI-dC), 100 mM KCl, 1.5 mM MgCl 2 , and 0.02 mM DTT for 20 min at 25°C. For specificity analyses, a 100-fold molar excess of unlabeled oligonucleotide competitors was preincubated for 15 min. When indicated, reaction mixtures were incubated with control antibody or anti-CRE-binding protein (CREB) antibodies (dilution, 1:10; Cell Signaling), which are specific to CREB and do not react with other members of the activating transcription factor family, for 20 min on ice before labeled oligonucleotides were added.
Transfection and luciferase assay. PC12 cells were seeded at 60% confluence in 35 mm dishes before transfection. Cells in the serum-free medium were transfected with PEI reagent as described previously (Boussif et al., 1995; Masutani et al., 1997) . After 24 hr, transfected cells were treated with 50 ng/ml NGF (Sigma). For controlling the efficiency of transfection, Renilla luciferase gene expression was monitored using pRL-TK. Luciferase gene expression, normalized by Renilla luciferase activity, was analyzed 24 hr later using an assay kit (Promega) with a luminometer. The luciferase assays were performed in duplicate. The relative fold activation of luciferase activity was calculated. PC12 cells were cotransfected with a bidirectional expression vector, pBI-EGFP, pBI-EGFP-wtTRX, pBI-EGFP-antisenseTRX, or pBI-EGFP-dmTRX in which the active site of TRX is inactivated , together with the pTet-Off vector (Clontech). After transfection, NGF was added to the medium. Cells expressing EGFP were examined with a fluorescent microscope (Bio-Rad, Hercules, CA) 24 or 48 hr later.
Immunofluorescence cell staining. PC12 cells were seeded before staining at 60% confluence in culture slides coated with poly-L-lysine. The cells were then fixed with 3.7% paraformaldehyde in PBS containing 10% FCS for 20 min at room temperature, which was followed by permeabilization for 10 min using 0.2% (w/v) Triton X-100 in PBS and blocking with PBS containing 5% bovine serum albumin and 10% FCS for 20 min. Slides were incubated with 2 g/ml mouse TRX antibody for 60 min and then washed with PBS. The slides were then incubated with 1 g/ml fluorescein isothiocyanate-labeled secondary antibody (Molecular Probes) for 60 min and were again washed with PBS. Hoechst 33324 (10 g/ml) was then added. Stained cells were examined using either the laser confocal or fluorescent microscope.
Results

NGF induced TRX expression in PC12 cells
We examined the effect of NGF on TRX expression in PC12 cells. The protein expression of TRX increased in PC12 cells 1.5-fold at 24 hr and 1.7-fold at 48 hr after NGF treatment (Fig. 1 A) . TRX mRNA also increased 2 hr after NGF treatment (Fig. 1 B) . To analyze the mechanism of induction of TRX by NGF treatment, we examined TRX promoter activity using PC12 cells transfected with TRX-Luc. Treatment with NGF significantly enhanced the activity of the TRX promoter (Fig. 1C) .
Identification of the NGF-responsive region in the TRX promoter
To understand the precise mechanism by which the TRX gene is activated by NGF, luciferase reporter constructs containing various deletion mutants of the TRX promoter region were used. A region of the gene between positions -263 and -217 relative to the translation start site was required for the NGF response (Fig. 2 A) . This region contains a sequence that resembles the consensus CRE, indicating the involvement of CRE in the NGF-dependent induction of TRX. We further analyzed the involvement of the CRE-like sequence in NGF responsiveness. Activation of the TRX gene by NGF was impaired in a vector that has mutations in this CRE-like sequence (Fig. 2 B) . We next analyzed CRE-binding protein by EMSA. NGF induced specific binding to the sequence, which was abolished by an excess amount of oligonucleotides encoding CRE but not SRE. Moreover, the binding was diminished by anti-CREB antibody but not by control antibody (Fig. 2C) .
TRX expression was suppressed by PD98059
PD98059, mitogen-activated protein kinase kinase (MEK) inhibitor, is known to suppress extracellular signal-regulated kinase (ERK)-and CRE-mediated activation by NGF. Treatment with NGF for 2 d induced neurite extension of PC12 cells. As reported previously, PD98059 (50 M) suppressed the NGF-induced morphological change in PC12 cells. We then tested the effect of PD98059 on NGF-mediated TRX gene activation. After 24 hr of NGF treatment, PD98059 blocked the NGF-induced activation of the TRX gene (Fig. 3A) . After 48 hr of NGF treatment, PD98059 also caused a decrease of TRX protein expression (Fig. 3B ).
NGF-induced nuclear translocation of TRX was blocked by PD98059
ERK is translocated from cytoplasm to nucleus on NGF treatment (Chen et al., 1992) . TRX is also translocated from cytoplasm to nucleus on exposure to H 2 O 2 or UV irradiation . To analyze the involvement of TRX in NGF-induced signaling, we studied the subcellular location of TRX on NGF treatment. After 16 hr of NGF (50 ng/ml) treatment, TRX was translocated to nuclei. Nuclear expression of TRX was positive in 86 Ϯ 3% of cells treated with NGF, whereas it was negative in control cells. The nuclear translocation of TRX was blocked by PD98059 (Fig. 4 A-C) . Nuclear expression was defined by costaining with Hoechst 33342 (Fig. 4 D,E) .
Overexpression of mutant TRX (C32S/C35S) or TRX antisense vector blocked NGF-induced neurite outgrowth of PC12 cells
We then examined whether TRX is required for NGF-dependent neurite outgrowth in PC12 cells. We transiently transfected PC12 cells with pBI-EGFP, pBI-EGFP-wtTRX, pBI-EGFP-antisenseTRX, or pBI-EGFP-dmTRX (32S/35S), in which the redox-active site of TRX was inactivated, together with the pTet-Off vector. The mutant TRX competitively inhibits TRX-dependent activation of transcription factors . After transfection, NGF (50 ng/ml) was added to the medium. We observed neurite outgrowth 24 and 48 hr after NGF treatment. Transfected cells were identified by the fluorescence of GFP. Cells with neurites were defined as cells that possessed at least one neurite of greater than one cell body diameter in length. Results are shown as percentages of the number of neuritepositive cells against the total number of transfected cells. At least 100 cells were assessed in each experiment. We repeated experiments three times. Seventy-four Ϯ 4% of cells transfected with the wild-type TRX vector and 56 Ϯ 2% of cells transfected with the control vector showed neurite outgrowth. In contrast, 8 Ϯ 1% of mutant TRX vector-transfected cells showed neurite outgrowth. In addition, only 17 Ϯ 1% of antisense TRX-transfected cells showed neurite outgrowth (Fig. 5) . Expression of the TRX dominant negative mutant or antisense TRX vectors may alter NGF-induced cell survival under serum-free conditions. To test this possibility, we analyzed apoptosis in cells transfected with the control, TRX dominant negative, and antisense TRX vectors under a serum-free condition, 48 hr after NGF treatment, by flow cytometric analysis. Overexpression of the TRX dominant negative or antisense TRX vector did not induce apoptosis under this condition (data not shown). These results suggest that TRX is required for NGF-dependent neurite outgrowth of PC12 cells.
Overexpression of mutant TRX (C32S/C35S) blocked CREmediated c-fos induction by NGF
TRX has been reported to regulate various transcription factors by facilitating either DNA binding or coactivator interaction (Ema et al., 1999) . Therefore, we analyzed whether TRX is involved in the regulation of NGFmediated activation through CRE. After treatment for 4 hr, NGF caused a 40-fold increase of luciferase activity in pGL3-c-fos (Ϫ99, ϩ42) containing CRE but no increase in pGL3-c-fos (Ϫ40, ϩ42), in which the CRE sequence was entirely deleted (Fig. 6 A) . The response to NGF of the reporter gene pGL3-c-fos (Ϫ99, ϩ42) was markedly suppressed by transfection with mutant TRX (C32S/C35S). The transactivation of c-fos was suppressed to 75% by mutant TRX (C32S/C35S) (Fig. 6 B) . In contrast, NGF caused a 50-fold increase in luciferase activity in SRE3-luc, which was not suppressed by overexpression of mutant TRX (C32S/C35S) (Fig. 6C) . 
Discussion
In the present study, we have shown that NGF induces TRX expression at the protein and mRNA levels in PC12 cells. We identified an NGF-responsive region positioned from -263 to -217 bp in the TRX gene by a luciferase assay. This region contained a CGTCA sequence, which bears a resemblance to that of the consensus CRE (Montminy et al., 1986) . Moreover, insertion of a mutation in the sequence abolished the response to NGF. EMSA analysis showed that NGF-induced binding to the sequence was competed by consensus CRE oligonucleotides and blocked by anti-CREB antibody. In addition, we showed that an MEK inhibitor, PD98059, suppressed NGF-induced TRX expression. NGF-induced CRE activation is mediated by ERK (Impey et al., 1998) . These results indicate that the TRX gene is induced by NGF through the ERK and CRE cascade. Studies are in progress to analyze the mechanism of the TRX gene induction by NGF. We also demonstrated that NGF induces nuclear translocation of TRX, as does PMA , UV irradiation , and hemin (Kim et al., 2001) . We showed that PD98059 blocks this effect of NGF, suggesting that ERK is involved in regulating the NGF-induced nuclear translocation of TRX. The mechanism and physiological significance of the translocation should be further investigated. The NGF-induced expression and nuclear translocation of TRX seems to be associated with the NGF-induced outgrowth of PC12 cells, because PD98059 suppressed both the NGF-induced neurite outgrowth and TRX expression as well as nuclear translocation (Figs. 3, 4) . More importantly, overexpression of dominant negative mutant TRX and antisense TRX vectors almost completely inhibited the neurite outgrowth (Fig. 5) . It is possible that expression of the TRX dominant negative mutant vector changed NGF-induced cell survival. However, overexpression of the dominant negative or antisense TRX vector did not induce apoptosis under a serumfree condition 48 hr after NGF treatment. These results strongly suggest that TRX is required for the neurite outgrowth of PC12 cells induced by NGF.
The IEGs, such as c-fos, have been believed to be required for NGF action. In the upstream regulatory region of the c-fos gene, CRE is critical for regulation of c-fos transcription in response to a variety of extracellular stimuli that induce neural differentiation (Sheng et al., 1988; Ahn et al., 1998) . We have shown that overexpression of the dominant negative mutant type of TRX blocks NGF-induced activation of the pGL3-c-fos (Ϫ99, ϩ42) reporter gene containing CRE but not pGL3-c-fos (Ϫ40, ϩ42) and SRE3-luc (Fig. 6 B,C) . Therefore, overexpression of a dominant negative TRX seemed not to cause a nonspecific effect but seemed to preferentially affect the CRE pathway. The mechanism of the suppression of CRE-mediated activation by a dominant negative TRX should be investigated further. These results indicate that TRX is necessary for NGF signaling through CRE, leading to c-fos expression. NGF induces the c-fos gene to high levels at 1 hr after NGF treatment, whereas augmentation of TRX expression is rather slow. Therefore, the initial phase of c-fos induction may not be attributable to the increased TRX, but the constitutively expressed TRX may potentiate the activation of AP-1. Upregulated TRX may exert its effect through sustained activation of AP-1 or some post-transcriptional mechanism to enhance NGF signaling. TRX regulates the activity of DNA-binding proteins, including Jun and Fos (AP-1), and interacts with an intranuclear reducing molecule, Redox factor 1 (Ref-1; Hirota et al., 1997) . AP-1 and Ref-1 have been reported to be involved in differentiation (Sheng and Greenberg, 1990; Chiarini et al., 2000) . Recently, we reported that TRX and Ref-1 regulate the interaction between transcription factors and coactivators (Ema et al., 1999) and that activation of CREB is regulated by TRX (Hirota et al., 2000) . Therefore, TRX may augment the interaction of CREB with DNA or coactivators to facilitate NGF signaling. Further study is needed to elucidate the mechanism of involvement of TRX in the NGF signaling pathway.
NGF has been shown to promote axonal regeneration (Hollowell et al., 1990) . Endoh et al. (1993) reported neurotrophic activity of TRX for cholinergic neurons. The present results confirmed and expanded this finding, suggesting that TRX is a neurotrophic cofactor that augments the effect of NGF on neurite outgrowth and neuronal regeneration.
NGF acts as a neuronal survival factor and has been shown to prevent the death of axotomized septal neurons (Pallage et al., 1986) . The ERK signaling pathway is not only critical for differentiation but also involved in cell survival (Xia et al., 1995) . NGF withdrawal causes apoptosis in PC12 cells, which is mediated by p38 MAPK and ASK1 (Xia et al., 1995; Kummer et al., 1997; Kanamoto et al., 2000) . TRX has been reported to act as an endogenous inhibitor of ASK1 and p38 MAPK (Saitoh et al., 1998; Hashimoto et al., 1999) , and NGF withdrawal also caused downregulation of TRX expression in PC12 cells (J. Bai, H. Nakamura, H. Masutani, and J. Yodoi, unpublished observations). These results indicate that maintenance of the TRX level by NGF plays a role in not only neurite outgrowth but also prevention of neuronal death. A protective role for TRX against neuronal damage has been shown. TRX expression is induced in astroglia after ischemia (Tomimoto et al., 1993) . Overexpression of TRX in transgenic mice attenuates focal cerebral ischemic injury and excitotoxic hippocampal injury (Takagi et al., 2000) . Decreased expression of TRX in Alzheimer's disease brain has also been reported (Lovell et al., 2000) . NGF administration has been proposed for maintaining cholinergic neurons in patients with Alzheimer's disease (Serrano Sanchez et al., 2001) . These studies and our results collectively indicate that administration of TRX may enhance the effect of NGF in neuronal diseases such as neurodegenerative disorders. Further study is in progress to clarify the therapeutic potential of TRX for neurodegenerative disorders.
